171 related articles for article (PubMed ID: 15992909)
21. Epididymitis after prostate brachytherapy.
Hoffelt SC; Wallner K; Merrick G
Urology; 2004 Feb; 63(2):293-6. PubMed ID: 14972474
[TBL] [Abstract][Full Text] [Related]
22. Four-year experience of interstitial permanent brachytherapy for Japanese men with localized prostate cancer.
Ishiyama H; Satoh T; Kitano M; Tsumura H; Kotani S; Okusa H; Uemae M; Baba S; Hayakawa K
Jpn J Clin Oncol; 2008 Jul; 38(7):469-73. PubMed ID: 18577509
[TBL] [Abstract][Full Text] [Related]
23. Stranded seed displacement, migration, and loss after permanent prostate brachytherapy as estimated by Day 0 fluoroscopy and 4-month postimplant pelvic x-ray.
Birckhead BJ; Fossum CC; Deufel CL; Furutani KM; Merrell KW; Schueler BA; Mynderse LA; Choo R; Davis BJ
Brachytherapy; 2016; 15(6):714-721. PubMed ID: 27542893
[TBL] [Abstract][Full Text] [Related]
24. Radiation exposure after permanent prostate brachytherapy.
Cattani F; Vavassori A; Polo A; Rondi E; Cambria R; Orecchia R; Tosi G
Radiother Oncol; 2006 Apr; 79(1):65-9. PubMed ID: 16564593
[TBL] [Abstract][Full Text] [Related]
25. Factors predicting an increased dose to the penile bulb in permanent seed prostate brachytherapy.
Taussky D; Haider M; McLean M; Yeung I; Williams T; Pearson S; Lockwood G; Crook J
Brachytherapy; 2004; 3(3):125-9. PubMed ID: 15533803
[TBL] [Abstract][Full Text] [Related]
26. Loose seeds vs. stranded seeds: a comparison of critical organ dosimetry and acute toxicity in (125)I permanent implant for low-risk prostate cancer.
Saibishkumar EP; Borg J; Yeung I; Cummins-Holder C; Landon A; Crook JM
Brachytherapy; 2008; 7(2):200-5. PubMed ID: 18362087
[TBL] [Abstract][Full Text] [Related]
27. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
28. Variations in international prostate symptom scores, uroflowmetric parameters, and prostate volume after (125)I permanent brachytherapy for localized prostate cancer.
Tanaka N; Fujimoto K; Hirao Y; Asakawa I; Hasegawa M; Konishi N
Urology; 2009 Aug; 74(2):407-11. PubMed ID: 19376570
[TBL] [Abstract][Full Text] [Related]
29. Severity categories of the International Prostate Symptom Score before, and urinary morbidity after, permanent prostate brachytherapy.
Gutman S; Merrick GS; Butler WM; Wallner KE; Allen Z; Galbreath RW; Adamovich E
BJU Int; 2006 Jan; 97(1):62-8. PubMed ID: 16336330
[TBL] [Abstract][Full Text] [Related]
30. Is a loose-seed nomogram still valid for prostate brachytherapy in a stranded-seed era?
Kudchadker RJ; Swanson DA; Kuban DA; Lee AK; Bruno TL; Frank SJ
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):623-7. PubMed ID: 18410998
[TBL] [Abstract][Full Text] [Related]
31. Improvements in prostate brachytherapy dosimetry due to seed stranding.
Lin K; Lee SP; Cho JS; Reiter RE; DeMarco JJ; Solberg TD
Brachytherapy; 2007; 6(1):44-8. PubMed ID: 17284385
[TBL] [Abstract][Full Text] [Related]
32. Is seminal vesicle implantation with permanent sources possible? A dose-volume histogram analysis in patients undergoing combined 103Pd implantation and external beam radiation for T3c prostate cancer.
Ho AY; Burri RJ; Jennings GT; Stone NN; Cesaretti JA; Stock RG
Brachytherapy; 2007; 6(1):38-43. PubMed ID: 17284384
[TBL] [Abstract][Full Text] [Related]
33. A study of a pretreatment method to predict the number of I-125 seeds required for prostate brachytherapy.
Al-Qaisieh B; Brearley E; St Clair S; Flynn A
Int J Radiat Oncol Biol Phys; 2006 May; 65(1):304-7. PubMed ID: 16618585
[TBL] [Abstract][Full Text] [Related]
34. Pulmonary embolization of permanently implanted radioactive palladium-103 seeds for carcinoma of the prostate.
Nag S; Vivekanandam S; MartÃnez-Monge R
Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):667-70. PubMed ID: 9336147
[TBL] [Abstract][Full Text] [Related]
35. Variability of prostate brachytherapy pre-implant dosimetry: a multi-institutional analysis.
Merrick GS; Butler WM; Wallner KE; Blasko JC; Michalski J; Aronowitz J; Grimm P; Moran BJ; McLaughlin PW; Usher J; Lief JH; Allen ZA
Brachytherapy; 2005; 4(4):241-51. PubMed ID: 16344253
[TBL] [Abstract][Full Text] [Related]
36. The use of linked seeds eliminates lung embolization following permanent seed implantation for prostate cancer.
Al-Qaisieh B; Carey B; Ash D; Bottomley D
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):397-9. PubMed ID: 15145154
[TBL] [Abstract][Full Text] [Related]
37. Prostate implant nomograms for the North American Scientific 103Pd seed.
Zheng JJ; Stevens RN
Med Dosim; 2003; 28(3):185-8. PubMed ID: 14563438
[TBL] [Abstract][Full Text] [Related]
38. Novel prostate brachytherapy technique: improved dosimetric and clinical outcome.
Nobes JP; Khaksar SJ; Hawkins MA; Cunningham MJ; Langley SE; Laing RW
Radiother Oncol; 2008 Jul; 88(1):121-6. PubMed ID: 18499289
[TBL] [Abstract][Full Text] [Related]
39. Quality assurance of I-125 seed permanent implant therapy using a self-color developing reflection-type dosimetry sheet film.
Furutani S; Ikushima H; Ozaki K; Oita M; Sasaki M; Takegawa Y; Nishitani H
Radiat Med; 2005 Nov; 23(7):474-7. PubMed ID: 16485537
[TBL] [Abstract][Full Text] [Related]
40. Androgen deprivation-mediated cytoreduction before interstitial brachytherapy for prostate cancer does not abrogate the elevated risk of urinary morbidity associated with larger initial prostate volume.
Petit JH; Gluck C; Kiger WS; Laury Henry D; Karasiewicz C; Talcott JA; Berg S; Holupka EJ; Kaplan ID
Brachytherapy; 2007; 6(4):267-71. PubMed ID: 17959423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
